CVS to Pay $315M in DOJ Settlement on Opioid Prescriptions and False Claims
DOJ says CVS and related entities agreed to pay $315 million to resolve allegations that CVS filled unlawful opioid prescriptions and resulting false claims between 2013 and 2025.
DOJ announced on October 13, 2026 that CVS Pharmacy Inc. and related corporate entities entered two settlement agreements resolving allegations that, from October 17, 2013 through December 2, 2025, CVS filled prescriptions unlawful under the Controlled Substances Act and submitted false claims to federal healthcare programs. The reported payment is $315 million, and the two agreements reportedly impose compliance obligations beyond the money itself. The source does not set out the allocation of the figure among False Claims Act, Controlled Substances Act and related penalties, or whether the resolution includes a deferred prosecution agreement or a corporate integrity agreement, so those structural details should be treated as unconfirmed until the agreements themselves are public. Three follow-ons matter for clients: the operational requirements the settlement places on pharmacy dispensing and prescriber verification; downstream exposure for health systems, prescribers and PBMs that supplied volume or data; and the interaction between federal relief and the separate multistate opioid settlements already covering CVS. The practical action is to re-scope dispensing controls, prescriber verification and record-retention duties at other chains against the settlement's compliance terms, and to watch for the unresolved allocation of penalties.